LaserSight (US) moves forward in laser correction trials:
This article was originally published in Clinica
LaserSight (US) has received FDA approval to proceed with Phase IIa clinical trials of its Compak-200 mini-excimer laser system for treatment of myopia. Trials will be performed at five locations in the US for corrections ranging from -1.5 to -10 dioptres.
You may also be interested in...
To be more transparent and allow more public discourse, the HHS now requires all its agencies to publish documents it uses to rationalize proposed rules and demonstration projects.
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from India's Glenmark.
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.